Virax Historical Balance Sheet

VRAX Stock

USD 1.29 0.01 0.78%

Trend analysis of Virax Biolabs Group balance sheet accounts such as Total Assets of 3.4 M, Short Long Term Debt Total of 210.1 K, Other Current Liabilities of 54 K or Total Current Liabilities of 144.4 K provides information on Virax Biolabs' total assets, liabilities, and equity, which is the actual value of Virax Biolabs Group to its prevalent stockholders. By breaking down trends over time using Virax Biolabs balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Virax Biolabs Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Virax Biolabs Group is a good buy for the upcoming year.

Virax Biolabs Inventory

72,912.47

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Virax Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Virax Biolabs Group at a specified time, usually calculated after every quarter, six months, or one year. Virax Biolabs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Virax Biolabs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Virax currently owns. An asset can also be divided into two categories, current and non-current.

Virax Biolabs Balance Sheet Chart

At this time, Virax Biolabs' Capital Stock is fairly stable compared to the past year. Net Working Capital is likely to rise to about 5.1 M in 2025, whereas Total Assets are likely to drop slightly above 3.4 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Virax Biolabs assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Virax Biolabs Group books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Virax Biolabs balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Virax Biolabs Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Virax Biolabs' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	146.3K	224.3K	201.9K	210.1K
Total Assets	9.8M	5.5M	6.3M	3.4M

Short Long Term Debt Total Total Assets

Virax Biolabs balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Other Assets	Short Term Investments	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		-0.63	-0.69	-0.69	0.96	0.89	0.74	-0.97	-0.82	-0.39	0.98	0.98	0.55	-0.4	-0.7	0.96	0.99	0.76	0.97	-0.67	0.76	0.45	0.86	0.57	0.56	-0.34
Short Long Term Debt Total	-0.63		0.88	0.66	-0.68	-0.67	-0.98	0.66	0.71	-0.18	-0.6	-0.6	-0.45	-0.3	0.68	-0.68	-0.62	-0.74	-0.67	0.99	-0.74	-0.41	-0.62	-0.53	-0.53	0.4
Other Current Liab	-0.69	0.88		0.92	-0.79	-0.87	-0.95	0.64	0.93	0.13	-0.6	-0.6	-0.75	-0.13	0.92	-0.79	-0.64	-0.96	-0.75	0.95	-0.96	-0.65	-0.86	-0.87	-0.86	0.65
Total Current Liabilities	-0.69	0.66	0.92		-0.81	-0.92	-0.79	0.6	0.95	0.51	-0.57	-0.57	-0.84	0.21	1.0	-0.8	-0.62	-0.95	-0.76	0.78	-0.95	-0.73	-0.92	-0.96	-0.96	0.72
Total Stockholder Equity	0.96	-0.68	-0.79	-0.81		0.97	0.8	-0.95	-0.9	-0.44	0.94	0.94	0.58	-0.36	-0.82	1.0	0.95	0.87	1.0	-0.74	0.87	0.56	0.88	0.7	0.71	-0.56
Net Tangible Assets	0.89	-0.67	-0.87	-0.92	0.97		0.81	-0.84	-0.97	-0.48	0.83	0.83	0.72	-0.3	-0.92	0.97	0.86	0.96	0.95	-0.76	0.96	0.68	0.94	0.85	0.86	-0.68
Current Deferred Revenue	0.74	-0.98	-0.95	-0.79	0.8	0.81		-0.75	-0.84	0.01	0.69	0.69	0.57	0.16	-0.81	0.8	0.72	0.86	0.78	-0.99	0.86	0.51	0.76	0.67	0.67	-0.5
Net Debt	-0.97	0.66	0.64	0.6	-0.95	-0.84	-0.75		0.74	0.29	-0.99	-0.99	-0.35	0.34	0.62	-0.95	-0.99	-0.7	-0.97	0.67	-0.7	-0.32	-0.73	-0.45	-0.45	0.33
Retained Earnings	-0.82	0.71	0.93	0.95	-0.9	-0.97	-0.84	0.74		0.4	-0.72	-0.72	-0.82	0.16	0.95	-0.89	-0.77	-0.98	-0.86	0.81	-0.98	-0.65	-0.97	-0.93	-0.91	0.62
Accounts Payable	-0.39	-0.18	0.13	0.51	-0.44	-0.48	0.01	0.29	0.4		-0.34	-0.34	-0.42	0.91	0.51	-0.44	-0.36	-0.32	-0.42	-0.07	-0.32	-0.36	-0.48	-0.48	-0.48	0.36
Cash	0.98	-0.6	-0.6	-0.57	0.94	0.83	0.69	-0.99	-0.72	-0.34		1.0	0.38	-0.41	-0.59	0.94	1.0	0.67	0.96	-0.61	0.67	0.35	0.75	0.44	0.43	-0.29
Cash And Short Term Investments	0.98	-0.6	-0.6	-0.57	0.94	0.83	0.69	-0.99	-0.72	-0.34	1.0		0.38	-0.41	-0.59	0.94	1.0	0.67	0.96	-0.61	0.67	0.35	0.75	0.44	0.43	-0.29
Common Stock Shares Outstanding	0.55	-0.45	-0.75	-0.84	0.58	0.72	0.57	-0.35	-0.82	-0.42	0.38	0.38		-0.13	-0.82	0.57	0.45	0.79	0.52	-0.57	0.79	0.75	0.89	0.89	0.87	-0.46
Non Current Liabilities Total	-0.4	-0.3	-0.13	0.21	-0.36	-0.3	0.16	0.34	0.16	0.91	-0.41	-0.41	-0.13		0.22	-0.36	-0.4	-0.06	-0.38	-0.24	-0.06	-0.11	-0.28	-0.13	-0.13	0.06
Total Liab	-0.7	0.68	0.92	1.0	-0.82	-0.92	-0.81	0.62	0.95	0.51	-0.59	-0.59	-0.82	0.22		-0.81	-0.64	-0.95	-0.77	0.79	-0.95	-0.72	-0.91	-0.95	-0.95	0.72
Net Invested Capital	0.96	-0.68	-0.79	-0.8	1.0	0.97	0.8	-0.95	-0.89	-0.44	0.94	0.94	0.57	-0.36	-0.81		0.95	0.87	1.0	-0.74	0.87	0.55	0.88	0.7	0.7	-0.56
Total Current Assets	0.99	-0.62	-0.64	-0.62	0.95	0.86	0.72	-0.99	-0.77	-0.36	1.0	1.0	0.45	-0.4	-0.64	0.95		0.71	0.97	-0.64	0.71	0.4	0.8	0.5	0.49	-0.31
Capital Stock	0.76	-0.74	-0.96	-0.95	0.87	0.96	0.86	-0.7	-0.98	-0.32	0.67	0.67	0.79	-0.06	-0.95	0.87	0.71		0.83	-0.84	1.0	0.74	0.93	0.92	0.93	-0.75
Net Working Capital	0.97	-0.67	-0.75	-0.76	1.0	0.95	0.78	-0.97	-0.86	-0.42	0.96	0.96	0.52	-0.38	-0.77	1.0	0.97	0.83		-0.72	0.83	0.51	0.85	0.64	0.64	-0.51
Short Term Debt	-0.67	0.99	0.95	0.78	-0.74	-0.76	-0.99	0.67	0.81	-0.07	-0.61	-0.61	-0.57	-0.24	0.79	-0.74	-0.64	-0.84	-0.72		-0.84	-0.5	-0.72	-0.66	-0.66	0.49
Common Stock	0.76	-0.74	-0.96	-0.95	0.87	0.96	0.86	-0.7	-0.98	-0.32	0.67	0.67	0.79	-0.06	-0.95	0.87	0.71	1.0	0.83	-0.84		0.74	0.93	0.92	0.93	-0.75
Other Assets	0.45	-0.41	-0.65	-0.73	0.56	0.68	0.51	-0.32	-0.65	-0.36	0.35	0.35	0.75	-0.11	-0.72	0.55	0.4	0.74	0.51	-0.5	0.74		0.71	0.73	0.79	-0.8
Short Term Investments	0.86	-0.62	-0.86	-0.92	0.88	0.94	0.76	-0.73	-0.97	-0.48	0.75	0.75	0.89	-0.28	-0.91	0.88	0.8	0.93	0.85	-0.72	0.93	0.71		0.89	0.87	-0.53
Non Currrent Assets Other	0.57	-0.53	-0.87	-0.96	0.7	0.85	0.67	-0.45	-0.93	-0.48	0.44	0.44	0.89	-0.13	-0.95	0.7	0.5	0.92	0.64	-0.66	0.92	0.73	0.89		0.99	-0.71
Property Plant And Equipment Gross	0.56	-0.53	-0.86	-0.96	0.71	0.86	0.67	-0.45	-0.91	-0.48	0.43	0.43	0.87	-0.13	-0.95	0.7	0.49	0.93	0.64	-0.66	0.93	0.79	0.87	0.99		-0.79
Short Long Term Debt	-0.34	0.4	0.65	0.72	-0.56	-0.68	-0.5	0.33	0.62	0.36	-0.29	-0.29	-0.46	0.06	0.72	-0.56	-0.31	-0.75	-0.51	0.49	-0.75	-0.8	-0.53	-0.71	-0.79

Click cells to compare fundamentals

Virax Biolabs Account Relationship Matchups

Virax Biolabs balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	94.1K	48.7K	9.8M	5.5M	6.3M	3.4M
Short Long Term Debt Total	179.5K	3.8K	146.3K	224.3K	201.9K	210.1K
Other Current Liab	654.3K	398.9K	550.0K	63.1K	56.8K	54.0K
Total Current Liabilities	871.4K	1.2M	908.4K	168.8K	152.0K	144.4K
Total Stockholder Equity	(596.2K)	(974.6K)	9.1M	5.4M	6.2M	6.5M
Net Debt	161.9K	(18.0K)	(9.2M)	(3.4M)	(3.0M)	(3.2M)
Retained Earnings	(4.6M)	(6.3M)	(11.8M)	(18.5M)	(16.7M)	(15.8M)
Accounts Payable	217.1K	846.5K	159.9K	45.6K	41.1K	39.0K
Cash	17.6K	21.8K	9.4M	3.6M	4.1M	2.9M
Cash And Short Term Investments	17.6K	21.8K	9.4M	3.6M	4.1M	2.9M
Liabilities And Stockholders Equity	94.1K	48.7K	9.8M	5.5M	6.3M	3.4M
Non Current Liabilities Total	217.1K	846.5K	0.0	176.3K	158.7K	232.4K
Inventory	21.1K	21.0K	24.1K	60.4K	69.4K	72.9K
Total Liab	871.4K	1.2M	908.4K	345.2K	310.7K	295.1K
Net Invested Capital	(650.7K)	(974.6K)	9.3M	5.4M	6.2M	6.5M
Total Current Assets	39.6K	48.7K	9.6M	4.4M	5.0M	3.1M
Accumulated Other Comprehensive Income	4.0M	5.4M	20.9M	23.9M	27.5M	28.8M
Capital Stock	265.0	999.0	1.6K	2.6K	3.0K	3.1K
Net Working Capital	(831.8K)	(1.2M)	8.7M	4.2M	4.8M	5.1M
Short Term Debt	179.5K	3.8K	146.3K	48.0K	43.2K	41.0K
Common Stock	265.0	999.0	1.6K	2.6K	3.0K	3.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Virax Historical Balance Sheet

Virax Biolabs Inventory

72,912.47

About Virax Balance Sheet Analysis

Virax Biolabs Balance Sheet Chart

Total Assets

Total Current Liabilities

Virax Biolabs balance sheet Correlations

Virax Biolabs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Virax Biolabs balance sheet Accounts

Also Currently Popular

Additional Tools for Virax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Short Term Debt	- 0.99	Current Deferred Revenue
Common Stock	- 0.98	Retained Earnings
Capital Stock	- 0.98	Retained Earnings